Journal ArticleDOI
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
TLDR
There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.About:
This article is published in Journal of Hepatology.The article was published on 2008-02-01. It has received 1172 citations till now. The article focuses on the topics: HBeAg & Hepatitis B.read more
Citations
More filters
Journal ArticleDOI
Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
TL;DR: Baseline and on-treatment prediction of response may help select patients for peginterferon therapy and can aid individualized treatment decisions concerning therapy continuation or discontinuation.
Journal ArticleDOI
Modeling Progress Toward Elimination of Hepatitis B in Australia
Karen McCulloch,Nicole Romero,Nicole Romero,Jennifer H MacLachlan,Jennifer H MacLachlan,Nicole Allard,Nicole Allard,Benjamin C Cowie,Benjamin C Cowie +8 more
TL;DR: This poster focuses on Australia, which has committed to national targets of 80% diagnosed, 20% on treatment, and a 30% reduction in deaths by 2022.
Journal ArticleDOI
The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country
Mehlika Toy,Fatih Oğuz Önder,Ramazan Idilman,Gökhan Kabaçam,Jan Hendrik Richardus,Mithat Bozdayi,Meral Akdogan,Zarife Kuloğlu,Aydan Kansu,Solko W. Schalm,Cihan Yurdaydin +10 more
TL;DR: Monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease.
Journal ArticleDOI
Real-time PCR assays for hepatitis B virus DNA quantification may require two different targets.
TL;DR: The HBV DNA level could be undervalued when using the COBAS TaqMan HBV Test version 2 for Chinese HBV infections owing to a mismatch with the primer/probe and a duplex real-time PCR assay based on the S and C regions was developed.
Journal ArticleDOI
Caractéristiques des souches virales responsables d’hépatites B chroniques en Algérie du Nord-Est
F. Khelifa,V. Thibault +1 more
TL;DR: In this article, the caracteristiques des souches de VHB ont ete etudiees au moyen de tests serologiques and par analyse phylogenique des genes codant une partie des regions precore, HBs et polymerase.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
TL;DR: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
Journal ArticleDOI
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.